Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models

Cancer Letters

Volumn 328, Issue 2, 2013, Pages 307-317

  Tiwari, Amit K ^a,d   Sodani, Kamlesh ^a   Dai, Chun ling ^a,c   Abuznait, Alaa H ^b   Singh, Satyakam ^a   Xiao, Zhi Jie ^a   Patel, Atish ^a   Talele, Tanaji T ^a   Fu, Liwu ^c   Kaddoumi, Amal ^b   Gallo, James M ^d   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ABC transporters; ABCB1 P gp; ABCC10 MRP7; ABCG2 BCRP; Multidrug resistance; Nilotinib

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DASATINIB; DOXORUBICIN; ERLOTINIB; IMATINIB; LAPATINIB; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; PACLITAXEL; PROTEIN ABCC10; SUNITINIB; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HEK293 CELLS; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR DOCKING SIMULATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 84870384407     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.001     Document Type: Article

References (50)

1. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
2. Deeley R.G., Westlake C., Cole S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86:849-899.
3. Gottesman M.M., Ambudkar S.V. Overview: ABC transporters and human disease. J. Bioenerg. Biomembr. 2001, 33:453-458.
4. Szakacs G., Varadi A., Ozvegy-Laczka C., Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today 2008, 13:379-393.
5. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
6. Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 2007, 1775:237-262.
7. Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., Ashby C.R., Huang Y., Robey R.W., Liang Y.J., Chen L.M., Shi C.J., Ambudkar S.V., Chen Z.S., Fu L.W. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008, 68:7905-7914.
8. Dai C.L., Liang Y.J., Wang Y.S., Tiwari A.K., Yan Y.Y., Wang F., Chen Z.S., Tong X.Z., Fu L.W. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009, 279:74-83.
9. Shi Z., Peng X.X., Kim I.W., Shukla S., Si Q.S., Robey R.W., Bates S.E., Shen T., Ashby C.R., Fu L.W., Ambudkar S.V., Chen Z.S. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007, 67:11012-11020.
10. Tiwari A.K., Sodani K., Wang S.R., Kuang Y.H., Ashby C.R., Chen X., Chen Z.S. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol. 2009, 78:153-161.
11. Shukla S., Robey R.W., Bates S.E., Ambudkar S.V. Sunitinib (Sutent(R), SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2. Drug Metab. Dispos. 2008.
12. Tiwari A.K., Sodani K., Dai C.L., Ashby C.R., Chen Z.S. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol. 2011, 12:570-594.
13. Breuninger L.M., Paul S., Gaughan K., Miki T., Chan A., Aaronson S.A., Kruh G.D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995, 55:5342-5347.
14. Kruh G.D., Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22:7537-7552.
15. Mao Q., Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005, 7:E118-133.
16. Polgar O., Robey R.W., Bates S.E. ABCG2: structure, function and role in drug response. Expert Opin. Drug Metab. Toxicol. 2008, 4:1-15.
17. Hopper-Borge E., Chen Z.S., Shchaveleva I., Belinsky M.G., Kruh G.D. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. 2004, 64:4927-4930.
18. Hopper-Borge E., Xu X., Shen T., Shi Z., Chen Z.S., Kruh G.D. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009, 69:178-184.
19. Shukla S., Chen Z.S., Ambudkar S.V. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist. Updates 2012.
20. Ozvegy-Laczka C., Cserepes J., Elkind N.B., Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updates 2005, 8:15-26.
21. Hegedus C., Ozvegy-Laczka C., Szakacs G., Sarkadi B. Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors?. Curr. Cancer Drug Targets 2009, 9:252-272.
22. Shen T., Kuang Y.H., Ashby C.R., Lei Y., Chen A., Zhou Y., Chen X., Tiwari A.K., Hopper-Borge E., Ouyang J., Chen Z.S. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009, 4:e7520.
23. Kuang Y.H., Shen T., Chen X., Sodani K., Hopper-Borge E., Tiwari A.K., Lee J.W., Fu L.W., Chen Z.S. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol. 2010, 79:154-161.
24. Shi Z., Tiwari A.K., Shukla S., Robey R.W., Kim I.W., Parmar S., Bates S.E., Si Q.S., Goldblatt C.S., Abraham I., Fu L.W., Ambudkar S.V., Chen Z.S. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem. Pharmacol. 2009, 77:781-793.
25. Villar V.H., Vogler O., Martinez-Serra J., Ramos R., Calabuig-Farinas S., Gutierrez A., Barcelo F., Martin-Broto J., Alemany R. Nilotinib counteracts p-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of Doxorubicin in soft tissue sarcomas. PLoS One 2012, 7:e37735.
26. Shukla S., Skoumbourdis A.P., Walsh M.J., Hartz A.M., Fung K.L., Wu C.P., Gottesman M.M., Bauer B., Thomas C.J., Ambudkar S.V. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol. Pharm. 2011, 8:1292-1302.
27. Akiyama S., Fojo A., Hanover J.A., Pastan I., Gottesman M.M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat. Cell Mol. Genet. 1985, 11:117-126.
28. Taguchi Y., Yoshida A., Takada Y., Komano T., Ueda K. Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett. 1997, 401:11-14.
29. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47:936-942.
30. Shi Z., Liang Y.J., Chen Z.S., Wang X.W., Wang X.H., Ding Y., Chen L.M., Yang X.P., Fu L.W. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol. Ther. 2006, 5:39-47.
31. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P.M., Trinh Y.T., Zhang Q., Urbatsch I.L., Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
32. Shi Z., Tiwari A.K., Shukla S., Robey R.W., Singh S., Kim I.W., Bates S.E., Peng X., Abraham I., Ambudkar S.V., Talele T.T., Fu L.W., Chen Z.S. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 2011, 71:3029-3041.
33. Rosenberg M.F., Bikadi Z., Chan J., Liu X., Ni Z., Cai X., Ford R.C., Mao Q. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 2010, 18:482-493.
34. Robey R.W., Honjo Y., Morisaki K., Nadjem T.A., Runge S., Risbood M., Poruchynsky M.S., Bates S.E. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 2003, 89:1971-1978.
35. Alqawi O., Bates S., Georges E. Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding. Biochem. J. 2004, 382:711-716.
36. Chen L.M., Liang Y.J., Ruan J.W., Ding Y., Wang X.W., Shi Z., Gu L.Q., Yang X.P., Fu L.W. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J. Pharm. Pharmacol. 2004, 56:1061-1066.
37. Gill K.K., Nazzal S., Kaddoumi A. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur. J. Pharm. Biopharm. 2011, 79:276-284.
38. Hegedus T., Orfi L., Seprodi A., Varadi A., Sarkadi B., Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 2002, 1587:318-325.
39. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R.D., Gilliland D.G., Griffin J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
40. Kaur P., Feldhahn N., Zhang B., Trageser D., Muschen M., Pertz V., Groffen J., Heisterkamp N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol. Cancer 2007, 6:67.
41. Kraus-Berthier L., Jan M., Guilbaud N., Naze M., Pierre A., Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin. Cancer Res. 2000, 6:297-304.
42. Manley P.W., Drueckes P., Fendrich G., Furet P., Liebetanz J., Martiny-Baron G., Mestan J., Trappe J., Wartmann M., Fabbro D. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim. Biophys. Acta 1804, 2010:445-453.
43. Deguchi Y., Kimura S., Ashihara E., Niwa T., Hodohara K., Fujiyama Y., Maekawa T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk. Res. 2008, 32:980-983.
44. Brendel C., Scharenberg C., Dohse M., Robey R.W., Bates S.E., Shukla S., Ambudkar S.V., Wang Y., Wennemuth G., Burchert A., Boudriot U., Neubauer A. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007, 21:1267-1275.
45. Mahon F.X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F., Belanger C., Manley P.W., Leroy C., Etienne G., Roche S., Pasquet J.M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68:9809-9816.
46. Nicolle E., Boccard J., Guilet D., Dijoux-Franca M.G., Zelefac F., Macalou S., Grosselin J., Schmidt J., Carrupt P.A., Di Pietro A., Boumendjel A. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur. J. Pharm. Sci. 2009, 38:39-46.
47. Dohse M., Scharenberg C., Shukla S., Robey R.W., Volkmann T., Deeken J.F., Brendel C., Ambudkar S.V., Neubauer A., Bates S.E. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab. Dispos. 2010, 38:1371-1380.
48. Klepsch F., Jabeen I., Chiba P., Ecker G.F. Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters. Curr. Pharm. Des. 2010, 16:1742-1752.
49. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J.D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O.G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354:2542-2551.
50. Stewart C.F., Leggas M., Schuetz J.D., Panetta J.C., Cheshire P.J., Peterson J., Daw N., Jenkins J.J., Gilbertson R., Germain G.S., Harwood F.C., Houghton P.J. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004, 64:7491-7499.